Abstract | AIM: METHODS: RESULTS: Both groups treated with FR139317 (high and low dose) have lower mortality rate (25.0 % and 28.6 % vs 50.0 %) and lower plasma level of ET-1 than that of vehicle [(3.6 +/- 1.2) ng/L and (4.9 +/- 1.5) ng/L vs (5.8 +/- 1.3) ng/L]. Comparing to vehicle group, left ventricular end-diastolic pressures of the FR139317-treated groups were improved significantly [(12 +/- 6) mmHg and (14 +/- 7) mmHg vs (22 +/- 9) mmHg]. FR139317 at a higher dose reduced the mean arterial pressure of the rats with congestive heart failure and decreased the plasma concentration of endothelin to a closer level of rats with normal heart function than lower dose. CONCLUSION:
|
Authors | X C Chen, X M Zhang, N S Luo, C Fang, Y M Liu, W Wu |
Journal | Acta pharmacologica Sinica
(Acta Pharmacol Sin)
Vol. 22
Issue 10
Pg. 896-900
(Oct 2001)
ISSN: 1671-4083 [Print] United States |
PMID | 11749771
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Azepines
- Endothelin Receptor Antagonists
- Endothelin-1
- Indoles
- Receptor, Endothelin A
- FR 139317
|
Topics |
- Animals
- Azepines
(pharmacology, therapeutic use)
- Endothelin Receptor Antagonists
- Endothelin-1
(blood)
- Heart Failure
(drug therapy, mortality, physiopathology)
- Hemodynamics
(drug effects)
- Indoles
(pharmacology, therapeutic use)
- Male
- Rats
- Rats, Wistar
- Receptor, Endothelin A
- Survival Rate
|